[go: up one dir, main page]

WO2023035571A1 - Synthesis method for esaxerenone and intermediate thereof - Google Patents

Synthesis method for esaxerenone and intermediate thereof Download PDF

Info

Publication number
WO2023035571A1
WO2023035571A1 PCT/CN2022/080532 CN2022080532W WO2023035571A1 WO 2023035571 A1 WO2023035571 A1 WO 2023035571A1 CN 2022080532 W CN2022080532 W CN 2022080532W WO 2023035571 A1 WO2023035571 A1 WO 2023035571A1
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
compound formula
limited
synthetic method
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/080532
Other languages
French (fr)
Chinese (zh)
Inventor
阮晶
张鑫鑫
严恭超
阮晓娜
张薇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Dingya Pharmaceutical Chemicals Co Ltd
Original Assignee
Shanghai Dingya Pharmaceutical Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Dingya Pharmaceutical Chemicals Co Ltd filed Critical Shanghai Dingya Pharmaceutical Chemicals Co Ltd
Publication of WO2023035571A1 publication Critical patent/WO2023035571A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to the field of organic synthesis, in particular, to a synthetic method for an eschacillinone intermediate, and in addition to a synthetic method for eschacillinone.
  • ethacillinone is (5P)-1-(2-hydroxyethyl)-N-[4-(methylsulfonyl)phenyl]-4-methyl-5-[2-(trifluoromethyl ) phenyl]-1H-pyrrole-3-carboxamide, the structural formula is as follows:
  • MR mineralocorticoid receptor
  • the preparation method of key intermediate IV is also reported, such as patent documents CN102186817A and WO2021078135A1.
  • the preparation methods of key intermediate IV disclosed in the above patent documents are all prepared by Suzuki coupling reaction, and the palladium catalyst used in this reaction is expensive. The cost is high, and ligands need to be added, which is not conducive to purification and industrial production.
  • the cyclization step of this route uses hydrogen chloride gas as the reaction material, which is highly corrosive, and the palladium metal catalyst used in the chlorine group removal step is expensive and costly, which is not conducive to industrial scale-up production.
  • the present invention provides a synthetic method of an eschacillinone intermediate, which has the advantages of high yield, simple aftertreatment, low cost, and ease of industrialization, while making the product meet the purity required for registration of raw materials.
  • One of purpose of the present invention is to provide a kind of synthetic method of new eschacillinone intermediate, to solve the existing synthetic method of eschacillinone intermediate that preparation yield is low, cost is high, post-processing is complicated and inconvenient Conducive to the problem of industrialized production.
  • the first aspect of the present invention provides a kind of synthetic method of new oxacillinone intermediate compound formula IV, and this synthetic method comprises the following steps:
  • step (1) The amide compound formula II obtained in step (1) is prepared through a dehydration reaction in the presence of a dehydrating agent and an acid-binding agent to obtain an isonitrile compound formula III;
  • step (3) The isonitrile compound formula III obtained in step (2) is cyclized with ethyl 2-butynoate to form the pyrrole ring compound formula IV in the presence of a base and a metal catalyst;
  • the process route is as follows:
  • the inert solvent described in step (1) includes but not limited to one or more of the group consisting of halogenated hydrocarbons, benzene, toluene, ether, xylene, nitrobenzene, and acetonitrile; One or more of imidazole, pyridine, tetrabutylammonium fluoride, 2,6-lutidine, potassium carbonate, N,N-diisopropylethylamine, sodium carbonate, and triethylamine; 2
  • the molar ratio of -(trifluoromethyl)phenylacetic acid to base is 1:0.5 ⁇ 1; the molar ratio of 2-(trifluoromethyl)phenylacetic acid to ethyl chloroformate or isobutyl chloroformate is 1:1 ⁇ 1.5; the reaction temperature is 0° C. to room temperature; the reaction time is 12 hours to 36 hours.
  • the dehydrating agent described in step (2) is one or more of P 2 O 5 , PCl 3 , SOCl 2 , COCl 2 , ArSO 2 Cl, POCl 3 ;
  • the acid-binding agent is an organic base Or inorganic base, described inorganic base is sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium tert-butoxide etc.;
  • Described organic base is triethylamine, diisopropylamine; Described solvent selects halogenated alkanes, two Chloromethane, dichloroethane.
  • the base in step (3) is Pr 3 N, pyridine, DBU, TEEDA; the metal catalyst is Cu 2 O, CuCl, CuI, CuBr, Cu(OMe) 2 , copper powder.
  • the second aspect of the present invention also provides the esacillinone intermediate compound formula IV, which is prepared by the above synthesis process.
  • the third aspect of the present invention also provides a synthetic method of a new oxacillinone intermediate compound formula V, the synthetic method comprising the following steps: the above-mentioned pyrrole ring compound formula IV in a solvent, under the condition of the presence of a base, and Reaction preparation obtains compound formula V;
  • the structural formula of intermediate compound formula V is as follows:
  • the X is halogen, and the A is hydroxyl or halogen.
  • the solvent is an alcohol solvent, a halogenated hydrocarbon solvent, an aromatic hydrocarbon solvent, an ether solvent or an amide solvent;
  • the alcohol solvent includes but not limited to ethanol;
  • the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform;
  • the aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene;
  • the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane
  • the amide solvent includes but not limited to N,N-dimethylacetamide, N,N-dimethylformamide;
  • the alkali is sodium hydroxide, potassium hydroxide, lithium hydroxide, tert-butanol Sodium, potassium tert-butoxide, cesium carbonate, sodium hydride, potassium carbonate, sodium carbonate, 4-dimethylaminopyridine, N,N-diisopropylethylamine,
  • the fourth aspect of the present invention also provides the esacillinone intermediate compound formula V, which is prepared by the aforementioned synthesis process.
  • the fifth aspect of the present invention also provides a kind of synthetic method of new ethacillinone, adopts following technical scheme:
  • the condensing agent is 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) and 1-hydroxybenzotriazole (HOBT), and the solvent is dry N,N-dimethylformamide (DMF), in addition to adding a certain amount of alkali, commonly used alkali is N,N-diisopropylethylamine (DIPEA), triethylamine, pyridine, hexafluorophosphoric acid Benzotriazol-1-yl-oxytripyrrolidinyl (PyBop), preferably N,N-diisopropylethylamine (DIPEA).
  • DIPEA N,N-diisopropylethylamine
  • PyBop Benzotriazol-1-yl-oxytripyrrolidinyl
  • DIPEA N,N-diisopropylethylamine
  • the sixth aspect of the present invention also provides a second new preparation method of ethacillinone, which adopts the following technical scheme: the above-mentioned ethacillinone intermediate compound formula V is reacted with a suitable acylating reagent to obtain the acid chloride compound formula VII, The acid chloride compound formula VII is acylated with 4-methanesulfonylanilide to obtain compound VI, wherein the structural formula of the acid chloride compound formula VII is as follows:
  • the acylating agent is oxalyl chloride, and the acylating reaction is preferably carried out in the presence of a base and a solvent, and the base is an organic base or an inorganic base, including but not limited to triethylamine, N , N-diisopropylethylamine;
  • the solvent is halogenated hydrocarbon solvent, aromatic hydrocarbon solvent, ether solvent or amide solvent;
  • the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform ;
  • the aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene;
  • the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane or the amides
  • Solvents include, but are not limited to, N,N-dimethylacetamide, N,N-dimethylformamide.
  • the seventh aspect of the present invention also provides eschacillinone, which is prepared by any one of the aforementioned synthesis processes.
  • the existing synthetic methods of oxacillinone intermediates have the problems of low preparation yield, high cost, complicated post-processing and unfavorable industrial production.
  • the application provides a kind of synthetic method of new eschacillinone intermediate compound formula IV, and this synthetic method comprises the following steps:
  • step (1) The amide compound formula II obtained in step (1) is prepared through a dehydration reaction in the presence of a dehydrating agent and an acid-binding agent to obtain an isonitrile compound formula III;
  • step (3) The isonitrile compound formula III obtained in step (2) is cyclized with ethyl 2-butynoate to form pyrrole ring compound IV in the presence of a base and a metal catalyst;
  • the process route is as follows:
  • the inert solvent described in step (1) includes but not limited to one or more of the group consisting of halogenated hydrocarbons, benzene, toluene, ether, xylene, nitrobenzene, and acetonitrile; One or more of imidazole, pyridine, tetrabutylammonium fluoride, 2,6-lutidine, potassium carbonate, N,N-diisopropylethylamine, sodium carbonate, and triethylamine; 2
  • the molar ratio of -(trifluoromethyl)phenylacetic acid to base is 1:0.5 ⁇ 1; the molar ratio of 2-(trifluoromethyl)phenylacetic acid to ethyl chloroformate or isobutyl chloroformate is 1:1 ⁇ 1.5; the reaction temperature is 0° C. to room temperature; the reaction time is 12 hours to 36 hours.
  • the dehydrating agent described in step (2) is one or more of P 2 O 5 , PCl 3 , SOCl 2 , COCl 2 , ArSO 2 Cl, POCl 3 ;
  • the acid-binding agent is an organic base Or inorganic base, described inorganic base is sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium tert-butoxide etc.;
  • Described organic base is triethylamine, diisopropylamine; Described solvent selects halogenated alkanes, two Chloromethane, dichloroethane.
  • the base in step (3) is Pr 3 N, pyridine, DBU, TEEDA; the metal catalyst is Cu 2 O, CuCl, CuI, CuBr, Cu(OMe) 2 , copper powder.
  • the raw material 2-(trifluoromethyl)phenylacetic acid (compound formula I) can be purchased.
  • the second aspect of the present invention also provides the esacillinone intermediate compound formula IV, which is prepared by the above synthesis process.
  • the third aspect of the present invention also provides a kind of synthetic method of new oxacillinone intermediate compound formula V, and this synthetic method is as follows:
  • the specific synthetic method comprises the following steps: the pyrrole ring compound formula IV obtained by the above synthesis is mixed with The compound formula V is prepared by reaction, wherein said X is halogen, and said A is hydroxyl or halogen.
  • the solvent is an alcohol solvent, a halogenated hydrocarbon solvent, an aromatic hydrocarbon solvent, an ether solvent or an amide solvent;
  • the alcohol solvent includes but not limited to ethanol;
  • the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform;
  • the aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene;
  • the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane
  • the amide solvent includes but not limited to N,N-dimethylacetamide, N,N-dimethylformamide;
  • the alkali is sodium hydroxide, potassium hydroxide, lithium hydroxide, tert-butanol Sodium, potassium tert-butoxide, cesium carbonate, sodium hydride, potassium carbonate, sodium carbonate, 4-dimethylaminopyridine, N,N-diisopropylethylamine,
  • the fourth aspect of the present invention also provides the esacillinone intermediate compound formula V, which is prepared by the aforementioned synthesis process.
  • the fifth aspect of the present invention also provides a new synthetic method of ixacillinone, the preparation method is as follows:
  • the specific synthesis method includes the following steps: condensing the above-mentioned oxacillinone intermediate compound formula V and 4-methanesulfonylaniline under the action of a condensing agent to obtain oxacillinone (compound formula VI).
  • the condensing agent is 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) and 1-hydroxybenzotriazole (HOBT), and the solvent is dry N,N-dimethylformamide (DMF), in addition to adding a certain amount of alkali, commonly used alkali is N,N-diisopropylethylamine (DIPEA), triethylamine, pyridine, hexafluorophosphoric acid Benzotriazol-1-yl-oxytripyrrolidinyl (PyBop), preferably N,N-diisopropylethylamine (DIPEA).
  • DIPEA N,N-diisopropylethylamine
  • PyBop Benzotriazol-1-yl-oxytripyrrolidinyl
  • DIPEA N,N-diisopropylethylamine
  • the sixth aspect of the present invention also provides the second new synthetic method of ixacillinone, the synthetic method is as follows:
  • the specific preparation method includes the following steps: react the above-mentioned ethacillinone intermediate compound V with a suitable acylating agent to obtain the acyl chloride compound VII, and then acylate the acyl chloride compound VII with 4-methylsulfonylanilide to obtain the compound VI.
  • the acylating agent is oxalyl chloride, and the acylating reaction is preferably carried out in the presence of a base and a solvent, and the base is an organic base or an inorganic base, including but not limited to triethylamine, N , N-diisopropylethylamine;
  • the solvent is halogenated hydrocarbon solvent, aromatic hydrocarbon solvent, ether solvent or amide solvent;
  • the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform ;
  • the aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene;
  • the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane or the amides
  • Solvents include, but are not limited to, N,N-dimethylacetamide, N,N-dimethylformamide.
  • the seventh aspect of the present invention also provides eschacillinone, which is prepared by any one of the aforementioned synthesis processes.
  • reaction solution was cooled to room temperature, and the pH was adjusted to 5-6 with 2N hydrochloric acid, and the layers were allowed to stand.
  • the aqueous phase was extracted twice with dichloromethane, and the organic phases were combined. , dried and concentrated to obtain 14.7 g of 1-(2-hydroxyethyl)4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid with a yield of 94%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Provided is a new synthesis method for an intermediate of esaxerenone. The method comprises: (1) reacting 2-(trifluoromethyl)phenylacetic acid as a raw material with ethyl chloroformate or isobutyl chloroformate in an inert solvent in the presence of an alkali to produce a mixed anhydride, then reacting same with ammonia to obtain a corresponding amide compound of formula II; (2) subjecting the amide compound of formula II obtained in step (1) to a dehydration reaction in the presence of a dehydrating agent and an acid-binding agent to obtain an isocyanide compound of formula III; and (3) subjecting the isocyanide compound of formula III obtained in step (2) to a cyclization reaction with ethyl 2-butynonate in the presence of an alkali and a metal catalyst to form a pyrrole ring compound of formula IV; and the reaction equation is shown below: Compared to the prior art, the technical solution of the present invention has the advantages of a high yield, a simple post-treatment, low costs and easy industrialization, etc.

Description

埃沙西林酮及其中间体的合成方法The synthetic method of ethacillinone and its intermediate 技术领域technical field

本发明涉及有机合成领域,具体而言,涉及一种埃沙西林酮中间体的合成方法,此外还涉及埃沙西林酮的合成方法。The present invention relates to the field of organic synthesis, in particular, to a synthetic method for an eschacillinone intermediate, and in addition to a synthetic method for eschacillinone.

背景技术Background technique

埃沙西林酮化学名称为(5P)-1-(2-羟乙基)-N-[4-(甲磺酰基)苯基]-4-甲基-5-[2-(三氟甲基)苯基]-1H-吡咯-3-羧酰胺,结构式如下:The chemical name of ethacillinone is (5P)-1-(2-hydroxyethyl)-N-[4-(methylsulfonyl)phenyl]-4-methyl-5-[2-(trifluoromethyl ) phenyl]-1H-pyrrole-3-carboxamide, the structural formula is as follows:

Figure PCTCN2022080532-appb-000001
Figure PCTCN2022080532-appb-000001

其是一种选择性盐皮质激素受体(MR)拮抗剂,被用于治疗高血压症。It is a selective mineralocorticoid receptor (MR) antagonist used in the treatment of hypertension.

目前,中国专利CN105164105A和CN105473552A报道了原研公司第一三共株式会社埃沙西林酮的合成路线。从上述专利申请中不难看出,关键中间体Ⅳ的构建是埃沙西林酮合成路线的核心之一。At present, Chinese patents CN105164105A and CN105473552A report the synthesis route of ethacillinone of Daiichi Sankyo Co., Ltd., the original research company. It is not difficult to see from the above patent application that the construction of the key intermediate IV is one of the cores of the synthetic route of ethacillinone.

Figure PCTCN2022080532-appb-000002
Figure PCTCN2022080532-appb-000002

而对关键中间体Ⅳ的制备方法也有报道,如专利文献CN102186817A和WO2021078135A1,上述专利文献公开的关键中间体Ⅳ的制备方法均是经Suzuki偶联反应制得,该反应使用的钯催化剂价格昂贵,成本高,还需加入配体,不利于纯化,不利于工业化生产。The preparation method of key intermediate IV is also reported, such as patent documents CN102186817A and WO2021078135A1. The preparation methods of key intermediate IV disclosed in the above patent documents are all prepared by Suzuki coupling reaction, and the palladium catalyst used in this reaction is expensive. The cost is high, and ligands need to be added, which is not conducive to purification and industrial production.

中国专利CN105164105A、CN105473552A报道了经环化制得关键中间体Ⅳ的合成路线。该路线以2-溴-1-[2-(三氟甲基)苯基]丙烷-1-酮为起始原料,与氰基乙酸乙酯反应得到中间体2。而后经环化、去除氯基团得到关键中间体Ⅳ。反应式如下:Chinese patents CN105164105A and CN105473552A report the synthesis route of the key intermediate IV through cyclization. This route uses 2-bromo-1-[2-(trifluoromethyl)phenyl]propan-1-one as the starting material and reacts with ethyl cyanoacetate to obtain intermediate 2. Then, through cyclization and removal of chlorine group, the key intermediate IV is obtained. The reaction formula is as follows:

Figure PCTCN2022080532-appb-000003
Figure PCTCN2022080532-appb-000003

该路线环化步骤使用了氯化氢气体作为反应物料,其具有强腐蚀性,且去除氯基团步骤使用的钯金属催化剂价格昂贵,成本高,不利于进行工业化放大生产。The cyclization step of this route uses hydrogen chloride gas as the reaction material, which is highly corrosive, and the palladium metal catalyst used in the chlorine group removal step is expensive and costly, which is not conducive to industrial scale-up production.

此外,开发具有高收率、高纯度、简便高效、低成本和易于工业化生产的药学活性化合物的制备方法仍充满挑战。因此,本发明提供一种埃沙西林酮中间体的合成方法,该方法具有收率高,后处理简单,成本低,易于工业化的优点,同时使产品具有符合原料药注册所需的纯度。In addition, the development of preparation methods for pharmaceutically active compounds with high yield, high purity, simplicity and efficiency, low cost and easy industrial production is still full of challenges. Therefore, the present invention provides a synthetic method of an eschacillinone intermediate, which has the advantages of high yield, simple aftertreatment, low cost, and ease of industrialization, while making the product meet the purity required for registration of raw materials.

发明内容Contents of the invention

本发明的目的之一在于提供一种新的埃沙西林酮中间体的合成方法,以解决现有的埃沙西林酮中间体的合成方法存在制备收率低、成本高、后处理复杂及不利于工业化生产的问题。One of purpose of the present invention is to provide a kind of synthetic method of new eschacillinone intermediate, to solve the existing synthetic method of eschacillinone intermediate that preparation yield is low, cost is high, post-processing is complicated and inconvenient Conducive to the problem of industrialized production.

为了实现上述目的,本发明第一方面提供了一种新的埃沙西林酮中间体化合物式Ⅳ的合成方法,该合成方法包括下列步骤:In order to achieve the above object, the first aspect of the present invention provides a kind of synthetic method of new oxacillinone intermediate compound formula IV, and this synthetic method comprises the following steps:

(1)将原料2-(三氟甲基)苯乙酸在惰性溶剂中,碱存在条件下,与氯甲酸乙酯或氯甲酸异丁酯反应生成混合酸酐,而后再与氨反应得到相应的酰胺化合物式Ⅱ;(1) The raw material 2-(trifluoromethyl)phenylacetic acid is reacted with ethyl chloroformate or isobutyl chloroformate in an inert solvent in the presence of a base to form a mixed anhydride, and then reacted with ammonia to obtain the corresponding amide Compound formula II;

(2)步骤(1)得到的酰胺化合物式Ⅱ在脱水剂和缚酸剂存在条件下经脱水反应制备得到异腈化合物式Ⅲ;(2) The amide compound formula II obtained in step (1) is prepared through a dehydration reaction in the presence of a dehydrating agent and an acid-binding agent to obtain an isonitrile compound formula III;

(3)步骤(2)得到的异腈化合物式Ⅲ与2-丁炔酸乙酯在碱和金属催化剂存在条件下环化形成吡咯环化合物式Ⅳ;(3) The isonitrile compound formula III obtained in step (2) is cyclized with ethyl 2-butynoate to form the pyrrole ring compound formula IV in the presence of a base and a metal catalyst;

工艺路线如下所示:The process route is as follows:

Figure PCTCN2022080532-appb-000004
Figure PCTCN2022080532-appb-000004

优选地,步骤(1)中所述的惰性溶剂包括但不限于卤代烃、苯、甲苯、乙醚、二甲苯、硝基苯、乙腈组成的组中的一种或多种;所述的碱为咪唑、吡啶、四丁基氟化铵、2,6-二甲基吡啶、碳酸钾、N,N-二异丙基乙胺、碳酸钠、三乙胺中的一种或多种;2-(三氟甲基)苯乙酸与碱的摩尔比为1:0.5~1;2-(三氟甲基)苯乙酸与氯甲酸乙酯或氯甲酸异丁酯的摩尔比为1:1~1.5;反应温度为0℃~室温;反应时间为12小时~36小时。Preferably, the inert solvent described in step (1) includes but not limited to one or more of the group consisting of halogenated hydrocarbons, benzene, toluene, ether, xylene, nitrobenzene, and acetonitrile; One or more of imidazole, pyridine, tetrabutylammonium fluoride, 2,6-lutidine, potassium carbonate, N,N-diisopropylethylamine, sodium carbonate, and triethylamine; 2 The molar ratio of -(trifluoromethyl)phenylacetic acid to base is 1:0.5~1; the molar ratio of 2-(trifluoromethyl)phenylacetic acid to ethyl chloroformate or isobutyl chloroformate is 1:1~ 1.5; the reaction temperature is 0° C. to room temperature; the reaction time is 12 hours to 36 hours.

优选地,步骤(2)中所述的脱水剂为P 2O 5,PCl 3,SOCl 2,COCl 2,ArSO 2Cl,POCl 3中的一种或多种;所述缚酸剂为有机碱或无机碱,所述无机碱为碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾、叔丁醇钾等;所述有机碱为三乙胺,二异丙胺;所述溶剂选用卤代烷烃,二氯甲烷,二氯乙烷。 Preferably, the dehydrating agent described in step (2) is one or more of P 2 O 5 , PCl 3 , SOCl 2 , COCl 2 , ArSO 2 Cl, POCl 3 ; the acid-binding agent is an organic base Or inorganic base, described inorganic base is sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium tert-butoxide etc.; Described organic base is triethylamine, diisopropylamine; Described solvent selects halogenated alkanes, two Chloromethane, dichloroethane.

优选地,步骤(3)中所述的碱为Pr 3N,吡啶pyridine,DBU,TEEDA;所述的金属催化剂为Cu 2O,CuCl,CuI,CuBr,Cu(OMe) 2,铜粉。 Preferably, the base in step (3) is Pr 3 N, pyridine, DBU, TEEDA; the metal catalyst is Cu 2 O, CuCl, CuI, CuBr, Cu(OMe) 2 , copper powder.

本发明的第二方面还提供了埃沙西林酮中间体化合物式Ⅳ,该埃沙西林酮中间体化合物式Ⅳ由上述合成工艺制备得到。The second aspect of the present invention also provides the esacillinone intermediate compound formula IV, which is prepared by the above synthesis process.

本发明的第三方面还提供了一种新的埃沙西林酮中间体化合物式Ⅴ的合成方法,其合成方法包括下列步骤:将上述吡咯环化合物式Ⅳ在溶剂中,碱存在条件下,与

Figure PCTCN2022080532-appb-000005
反应制备得到化合物式Ⅴ;中间体化合物式Ⅴ的结构式如下所示: The third aspect of the present invention also provides a synthetic method of a new oxacillinone intermediate compound formula V, the synthetic method comprising the following steps: the above-mentioned pyrrole ring compound formula IV in a solvent, under the condition of the presence of a base, and
Figure PCTCN2022080532-appb-000005
Reaction preparation obtains compound formula V; The structural formula of intermediate compound formula V is as follows:

Figure PCTCN2022080532-appb-000006
Figure PCTCN2022080532-appb-000006

所述X为卤素,所述A为羟基或卤素。The X is halogen, and the A is hydroxyl or halogen.

优选地,所述溶剂为醇溶剂,卤代烃溶剂,芳族烃类溶剂,醚类溶剂或酰胺类溶剂;所述的醇溶剂包括但不限于乙醇;所述的卤代烃溶剂包括但不限于二氯甲烷或氯仿;所述的芳族烃类溶剂包括但不限于甲苯、苯、二甲苯或硝基苯;所述的醚类溶剂包括但不限于四氢呋喃、1,4-二氧六环或所述的酰胺类溶剂包括但不限于N,N-二甲基乙酰胺、N,N-二甲基甲酰胺;所述碱为氢氧化钠、氢氧化钾、氢氧化锂、叔丁醇钠、叔丁醇钾、碳酸铯、氢化钠、碳酸钾、碳酸钠、4-二甲基氨基吡啶、N,N-二异丙基乙胺、三乙胺或吡啶;优选氢氧化钠、氢氧化锂;该步骤反应温度为室温~80℃,优选为室温~60℃,反应时间为1~20小时,优选为2~3小时。Preferably, the solvent is an alcohol solvent, a halogenated hydrocarbon solvent, an aromatic hydrocarbon solvent, an ether solvent or an amide solvent; the alcohol solvent includes but not limited to ethanol; the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform; the aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene; the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane Or the amide solvent includes but not limited to N,N-dimethylacetamide, N,N-dimethylformamide; the alkali is sodium hydroxide, potassium hydroxide, lithium hydroxide, tert-butanol Sodium, potassium tert-butoxide, cesium carbonate, sodium hydride, potassium carbonate, sodium carbonate, 4-dimethylaminopyridine, N,N-diisopropylethylamine, triethylamine or pyridine; preferably sodium hydroxide, hydrogen Lithium oxide; the reaction temperature in this step is room temperature to 80°C, preferably room temperature to 60°C, and the reaction time is 1 to 20 hours, preferably 2 to 3 hours.

本发明的第四方面还提供了埃沙西林酮中间体化合物式Ⅴ,该埃沙西林酮中间体化合物式Ⅴ由前述合成工艺制备得到。The fourth aspect of the present invention also provides the esacillinone intermediate compound formula V, which is prepared by the aforementioned synthesis process.

本发明的第五方面还提供了一种新的埃沙西林酮的合成方法,采用如下技术方案:The fifth aspect of the present invention also provides a kind of synthetic method of new ethacillinone, adopts following technical scheme:

上述埃沙西林酮中间体化合物式Ⅴ与4-甲磺酰基苯胺在缩合剂作用下经缩合反应得到化合物式Ⅵ,其中化合物式Ⅵ的结构式如下所示:The above-mentioned oxacillinone intermediate compound formula V and 4-methanesulfonyl aniline undergo condensation reaction under the action of a condensing agent to obtain compound formula VI, wherein the structural formula of compound formula VI is as follows:

Figure PCTCN2022080532-appb-000007
Figure PCTCN2022080532-appb-000007

优选地,所述的缩合剂为1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐(EDCI)和1-羟基苯并三氮唑(HOBT),溶剂为干燥的N,N-二甲基甲酰胺(DMF),此外还要加入一定量的碱,常用的碱为N,N-二异丙基乙胺(DIPEA)、三乙胺、吡啶、六氟磷酸苯并三唑-1-基-氧基三吡咯烷基(PyBop),优选N,N-二异丙基乙胺(DIPEA)。Preferably, the condensing agent is 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) and 1-hydroxybenzotriazole (HOBT), and the solvent is dry N,N-dimethylformamide (DMF), in addition to adding a certain amount of alkali, commonly used alkali is N,N-diisopropylethylamine (DIPEA), triethylamine, pyridine, hexafluorophosphoric acid Benzotriazol-1-yl-oxytripyrrolidinyl (PyBop), preferably N,N-diisopropylethylamine (DIPEA).

本发明的第六方面还提供了第二种新的埃沙西林酮的制备方法,采用如下技术方案:上述埃沙西林酮中间体化合物式Ⅴ与合适的酰化试剂反应得到酰氯化合物式Ⅶ,酰氯化合物式Ⅶ再与4-甲磺酰基苯胺发生酰基化反应得到化合物Ⅵ,其中酰氯化合物式Ⅶ的结构式如下所示:The sixth aspect of the present invention also provides a second new preparation method of ethacillinone, which adopts the following technical scheme: the above-mentioned ethacillinone intermediate compound formula V is reacted with a suitable acylating reagent to obtain the acid chloride compound formula VII, The acid chloride compound formula VII is acylated with 4-methanesulfonylanilide to obtain compound VI, wherein the structural formula of the acid chloride compound formula VII is as follows:

Figure PCTCN2022080532-appb-000008
Figure PCTCN2022080532-appb-000008

优选地,所述的酰化试剂为草酰氯,所述的酰基化反应优选在碱和溶剂存在的条件 下进行,所述的碱为有机碱或无机碱,包括但不限于三乙胺、N,N-二异丙基乙胺;所述的溶剂为卤代烃溶剂,芳族烃类溶剂,醚类溶剂或酰胺类溶剂;所述的卤代烃溶剂包括但不限于二氯甲烷或氯仿;所述的芳族烃类溶剂包括但不限于甲苯、苯、二甲苯或硝基苯;所述的醚类溶剂包括但不限于四氢呋喃、1,4-二氧六环或所述的酰胺类溶剂包括但不限于N,N-二甲基乙酰胺、N,N-二甲基甲酰胺。Preferably, the acylating agent is oxalyl chloride, and the acylating reaction is preferably carried out in the presence of a base and a solvent, and the base is an organic base or an inorganic base, including but not limited to triethylamine, N , N-diisopropylethylamine; the solvent is halogenated hydrocarbon solvent, aromatic hydrocarbon solvent, ether solvent or amide solvent; the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform ; The aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene; the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane or the amides Solvents include, but are not limited to, N,N-dimethylacetamide, N,N-dimethylformamide.

本发明的第七方面还提供了埃沙西林酮,该埃沙西林酮由前述任一项合成工艺制备得到。The seventh aspect of the present invention also provides eschacillinone, which is prepared by any one of the aforementioned synthesis processes.

应用本发明的技术方案,避免使用昂贵的钯催化剂,降低了成本;同时避免了使用配体,后处理简单,易于纯化;避免使用强腐蚀性的氯化氢气体,利于工业化放大生产;相比与现有文献CN101006052A,应用本发明的技术方案制备埃沙西林酮中间体化合物式Ⅳ的收率提高了57.6个百分点。Applying the technical scheme of the present invention avoids the use of expensive palladium catalysts and reduces the cost; simultaneously avoids the use of ligands, and is simple in post-treatment and easy to purify; avoids the use of highly corrosive hydrogen chloride gas, which is beneficial to industrialized scale-up production; compared with existing According to the document CN101006052A, the yield of the eschacillinone intermediate compound formula IV is increased by 57.6 percentage points by applying the technical solution of the present invention.

具体实施方式Detailed ways

需要说明的是,在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合。下面将结合实施例来详细说明本发明。It should be noted that, in the case of no conflict, the embodiments in the present application and the features in the embodiments can be combined with each other. The present invention will be described in detail below in conjunction with examples.

正如背景技术中所描述的,现有的埃沙西林酮中间体的合成方法存在制备收率低、成本高、后处理复杂及不利于工业化生产的问题。为了解决上述技术问题,本申请提供了一种新的埃沙西林酮中间体化合物式Ⅳ的合成方法,该合成方法包括下列步骤:As described in the background technology, the existing synthetic methods of oxacillinone intermediates have the problems of low preparation yield, high cost, complicated post-processing and unfavorable industrial production. In order to solve the above-mentioned technical problem, the application provides a kind of synthetic method of new eschacillinone intermediate compound formula IV, and this synthetic method comprises the following steps:

(1)将原料2-(三氟甲基)苯乙酸在惰性溶剂中,碱存在条件下,与氯甲酸乙酯或氯甲酸异丁酯反应生成混合酸酐,而后再与氨反应得到相应的酰胺化合物式Ⅱ;(1) The raw material 2-(trifluoromethyl)phenylacetic acid is reacted with ethyl chloroformate or isobutyl chloroformate in an inert solvent in the presence of a base to form a mixed anhydride, and then reacted with ammonia to obtain the corresponding amide Compound formula II;

(2)步骤(1)得到的酰胺化合物式Ⅱ在脱水剂和缚酸剂存在条件下经脱水反应制备得到异腈化合物式Ⅲ;(2) The amide compound formula II obtained in step (1) is prepared through a dehydration reaction in the presence of a dehydrating agent and an acid-binding agent to obtain an isonitrile compound formula III;

(3)步骤(2)得到的异腈化合物式Ⅲ与2-丁炔酸乙酯在碱和金属催化剂存在条件下环化形成吡咯环化合物Ⅳ;(3) The isonitrile compound formula III obtained in step (2) is cyclized with ethyl 2-butynoate to form pyrrole ring compound IV in the presence of a base and a metal catalyst;

工艺路线如下所示:The process route is as follows:

Figure PCTCN2022080532-appb-000009
Figure PCTCN2022080532-appb-000009

优选地,步骤(1)中所述的惰性溶剂包括但不限于卤代烃、苯、甲苯、乙醚、二甲苯、硝基苯、乙腈组成的组中的一种或多种;所述的碱为咪唑、吡啶、四丁基氟化铵、2,6-二甲基吡啶、碳酸钾、N,N-二异丙基乙胺、碳酸钠、三乙胺中的一种或多种;2-(三氟甲基)苯乙酸与碱的摩尔比为1:0.5~1;2-(三氟甲基)苯乙酸与氯甲酸乙酯或氯甲酸异丁酯的摩尔比为1:1~1.5;反应温度为0℃~室温;反应时间为12小时~36小时。Preferably, the inert solvent described in step (1) includes but not limited to one or more of the group consisting of halogenated hydrocarbons, benzene, toluene, ether, xylene, nitrobenzene, and acetonitrile; One or more of imidazole, pyridine, tetrabutylammonium fluoride, 2,6-lutidine, potassium carbonate, N,N-diisopropylethylamine, sodium carbonate, and triethylamine; 2 The molar ratio of -(trifluoromethyl)phenylacetic acid to base is 1:0.5~1; the molar ratio of 2-(trifluoromethyl)phenylacetic acid to ethyl chloroformate or isobutyl chloroformate is 1:1~ 1.5; the reaction temperature is 0° C. to room temperature; the reaction time is 12 hours to 36 hours.

优选地,步骤(2)中所述的脱水剂为P 2O 5,PCl 3,SOCl 2,COCl 2,ArSO 2Cl,POCl 3中的一种或多种;所述缚酸剂为有机碱或无机碱,所述无机碱为碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾、叔丁醇钾等;所述有机碱为三乙胺,二异丙胺;所述溶剂选用卤代烷烃,二氯甲烷,二氯乙烷。 Preferably, the dehydrating agent described in step (2) is one or more of P 2 O 5 , PCl 3 , SOCl 2 , COCl 2 , ArSO 2 Cl, POCl 3 ; the acid-binding agent is an organic base Or inorganic base, described inorganic base is sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium tert-butoxide etc.; Described organic base is triethylamine, diisopropylamine; Described solvent selects halogenated alkanes, two Chloromethane, dichloroethane.

优选地,步骤(3)中所述的碱为Pr 3N,吡啶pyridine,DBU,TEEDA;所述的金属催化剂为Cu 2O,CuCl,CuI,CuBr,Cu(OMe) 2,铜粉。 Preferably, the base in step (3) is Pr 3 N, pyridine, DBU, TEEDA; the metal catalyst is Cu 2 O, CuCl, CuI, CuBr, Cu(OMe) 2 , copper powder.

原料2-(三氟甲基)苯乙酸(化合物式Ⅰ)可以通过购买得到。The raw material 2-(trifluoromethyl)phenylacetic acid (compound formula I) can be purchased.

本发明的第二方面还提供了埃沙西林酮中间体化合物式Ⅳ,该埃沙西林酮中间体化合物式Ⅳ由上述合成工艺制备得到。The second aspect of the present invention also provides the esacillinone intermediate compound formula IV, which is prepared by the above synthesis process.

本发明的第三方面还提供了一种新的埃沙西林酮中间体化合物式Ⅴ的合成方法,该合成方法如下:The third aspect of the present invention also provides a kind of synthetic method of new oxacillinone intermediate compound formula V, and this synthetic method is as follows:

Figure PCTCN2022080532-appb-000010
Figure PCTCN2022080532-appb-000010

具体的合成方法包括下列步骤:将上述合成得到的吡咯环化合物式Ⅳ在溶剂中,碱存在条件下,与

Figure PCTCN2022080532-appb-000011
反应制备得到化合物式Ⅴ,其中所述X为卤素,所述A为羟基或卤素。 The specific synthetic method comprises the following steps: the pyrrole ring compound formula IV obtained by the above synthesis is mixed with
Figure PCTCN2022080532-appb-000011
The compound formula V is prepared by reaction, wherein said X is halogen, and said A is hydroxyl or halogen.

优选地,所述溶剂为醇溶剂,卤代烃溶剂,芳族烃类溶剂,醚类溶剂或酰胺类溶剂;所述的醇溶剂包括但不限于乙醇;所述的卤代烃溶剂包括但不限于二氯甲烷或氯仿;所述的芳族烃类溶剂包括但不限于甲苯、苯、二甲苯或硝基苯;所述的醚类溶剂包括但不限于四氢呋喃、1,4-二氧六环或所述的酰胺类溶剂包括但不限于N,N-二甲基乙酰胺、N,N-二甲基甲酰胺;所述碱为氢氧化钠、氢氧化钾、氢氧化锂、叔丁醇钠、叔丁醇钾、碳酸铯、氢化钠、碳酸钾、碳酸钠、4-二甲基氨基吡啶、N,N-二异丙基乙胺、三乙胺或吡啶;优选氢氧化钠、氢氧化锂;该步骤反应温度为室温~80℃,优选为室温~60℃,反应时间为1~20小时,优选为2~3小时。Preferably, the solvent is an alcohol solvent, a halogenated hydrocarbon solvent, an aromatic hydrocarbon solvent, an ether solvent or an amide solvent; the alcohol solvent includes but not limited to ethanol; the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform; the aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene; the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane Or the amide solvent includes but not limited to N,N-dimethylacetamide, N,N-dimethylformamide; the alkali is sodium hydroxide, potassium hydroxide, lithium hydroxide, tert-butanol Sodium, potassium tert-butoxide, cesium carbonate, sodium hydride, potassium carbonate, sodium carbonate, 4-dimethylaminopyridine, N,N-diisopropylethylamine, triethylamine or pyridine; preferably sodium hydroxide, hydrogen Lithium oxide; the reaction temperature in this step is room temperature to 80°C, preferably room temperature to 60°C, and the reaction time is 1 to 20 hours, preferably 2 to 3 hours.

本发明的第四方面还提供了埃沙西林酮中间体化合物式Ⅴ,该埃沙西林酮中间体化合物式Ⅴ由前述合成工艺制备得到。The fourth aspect of the present invention also provides the esacillinone intermediate compound formula V, which is prepared by the aforementioned synthesis process.

本发明的第五方面还提供了一种新的埃沙西林酮的合成方法,该制备方法如下:The fifth aspect of the present invention also provides a new synthetic method of ixacillinone, the preparation method is as follows:

Figure PCTCN2022080532-appb-000012
Figure PCTCN2022080532-appb-000012

具体的合成方法包括下列步骤:将上述埃沙西林酮中间体化合物式Ⅴ与4-甲磺酰基苯胺在缩合剂作用下经缩合反应得到埃沙西林酮(化合物式Ⅵ)。The specific synthesis method includes the following steps: condensing the above-mentioned oxacillinone intermediate compound formula V and 4-methanesulfonylaniline under the action of a condensing agent to obtain oxacillinone (compound formula VI).

优选地,所述的缩合剂为1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐(EDCI)和1-羟基苯并三氮唑(HOBT),溶剂为干燥的N,N-二甲基甲酰胺(DMF),此外还要加入一定量的碱,常用的碱为N,N-二异丙基乙胺(DIPEA)、三乙胺、吡啶、六氟磷酸苯并三唑-1-基-氧基三吡咯烷基(PyBop),优选N,N-二异丙基乙胺(DIPEA)。Preferably, the condensing agent is 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) and 1-hydroxybenzotriazole (HOBT), and the solvent is dry N,N-dimethylformamide (DMF), in addition to adding a certain amount of alkali, commonly used alkali is N,N-diisopropylethylamine (DIPEA), triethylamine, pyridine, hexafluorophosphoric acid Benzotriazol-1-yl-oxytripyrrolidinyl (PyBop), preferably N,N-diisopropylethylamine (DIPEA).

本发明的第六方面还提供了第二种新的埃沙西林酮的合成方法,该合成方法如下:The sixth aspect of the present invention also provides the second new synthetic method of ixacillinone, the synthetic method is as follows:

Figure PCTCN2022080532-appb-000013
Figure PCTCN2022080532-appb-000013

具体的制备方法包括下列步骤:将上述埃沙西林酮中间体化合物式Ⅴ与合适的酰化 试剂反应得到酰氯化合物式Ⅶ,酰氯化合物式Ⅶ再与4-甲磺酰基苯胺发生酰基化反应得到化合物Ⅵ。The specific preparation method includes the following steps: react the above-mentioned ethacillinone intermediate compound V with a suitable acylating agent to obtain the acyl chloride compound VII, and then acylate the acyl chloride compound VII with 4-methylsulfonylanilide to obtain the compound VI.

优选地,所述的酰化试剂为草酰氯,所述的酰基化反应优选在碱和溶剂存在的条件下进行,所述的碱为有机碱或无机碱,包括但不限于三乙胺、N,N-二异丙基乙胺;所述的溶剂为卤代烃溶剂,芳族烃类溶剂,醚类溶剂或酰胺类溶剂;所述的卤代烃溶剂包括但不限于二氯甲烷或氯仿;所述的芳族烃类溶剂包括但不限于甲苯、苯、二甲苯或硝基苯;所述的醚类溶剂包括但不限于四氢呋喃、1,4-二氧六环或所述的酰胺类溶剂包括但不限于N,N-二甲基乙酰胺、N,N-二甲基甲酰胺。Preferably, the acylating agent is oxalyl chloride, and the acylating reaction is preferably carried out in the presence of a base and a solvent, and the base is an organic base or an inorganic base, including but not limited to triethylamine, N , N-diisopropylethylamine; the solvent is halogenated hydrocarbon solvent, aromatic hydrocarbon solvent, ether solvent or amide solvent; the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform ; The aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene; the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane or the amides Solvents include, but are not limited to, N,N-dimethylacetamide, N,N-dimethylformamide.

本发明的第七方面还提供了埃沙西林酮,该埃沙西林酮由前述任一项合成工艺制备得到。The seventh aspect of the present invention also provides eschacillinone, which is prepared by any one of the aforementioned synthesis processes.

应用本发明的技术方案,避免使用昂贵的钯催化剂,降低了成本;同时避免了使用配体,后处理简单,易于纯化;避免使用强腐蚀性的氯化氢气体,利于工业化放大生产;相比与现有文献CN101006052A,应用本发明的技术方案制备埃沙西林酮中间体化合物式Ⅳ的收率提高了57.6个百分点。Applying the technical scheme of the present invention avoids the use of expensive palladium catalysts and reduces the cost; simultaneously avoids the use of ligands, and is simple in post-treatment and easy to purify; avoids the use of highly corrosive hydrogen chloride gas, which is beneficial to industrialized scale-up production; compared with existing According to the document CN101006052A, the yield of the eschacillinone intermediate compound formula IV is increased by 57.6 percentage points by applying the technical solution of the present invention.

实施例1 2-(三氟甲基)苯乙酰胺(酰胺化合物式Ⅱ)的合成The synthesis of embodiment 1 2-(trifluoromethyl) phenylacetamide (amide compound formula II)

Figure PCTCN2022080532-appb-000014
Figure PCTCN2022080532-appb-000014

向500mL 1,4-二氧六环溶剂中加入2-(三氟甲基)苯乙酸20.4g(0.1mol,1eq)和氯甲酸乙酯13.0g(0.12mol,1.2eq),吡啶4.7g(0.06mol,0.6eq)和11.9g(0.15mol,1.5eq)碳酸氢铵,在室温条件下搅拌12小时,检测反应完全,加入乙酸乙酯和食盐水萃取,将有机相干燥,浓缩,得到粗品,再用乙酸乙酯和石油醚结晶,得到酰胺化合物式Ⅱ19.9g,收率98.0%。Add 20.4g (0.1mol, 1eq) of 2-(trifluoromethyl)phenylacetic acid and 13.0g (0.12mol, 1.2eq) of ethyl chloroformate to 500mL 1,4-dioxane solvent, pyridine 4.7g ( 0.06mol, 0.6eq) and 11.9g (0.15mol, 1.5eq) of ammonium bicarbonate were stirred at room temperature for 12 hours, the reaction was detected to be complete, ethyl acetate and brine were added for extraction, the organic phase was dried and concentrated to obtain a crude product, Then crystallize with ethyl acetate and petroleum ether to obtain 19.9 g of amide compound formula II with a yield of 98.0%.

实施例2 异腈化合物式Ⅲ的合成The synthesis of embodiment 2 isocyanide compound formula III

Figure PCTCN2022080532-appb-000015
Figure PCTCN2022080532-appb-000015

将10.2g 2-(三氟甲基)苯乙酰胺(0.05mol)溶解在100mL二氯乙烷中,加入12.6g三乙胺(0.125mol),将反应体系温度降至-10℃以下,滴加0.05mol三氯氧磷,约20分钟左右滴加完毕,控制反应温度在0℃以下继续搅拌1小时,然后升温至25~30℃向反应液中滴加 20%碳酸钠溶液,滴加完毕后继续搅拌5~10分钟,静置分层,有机相用5%碳酸钠溶液洗涤2次,用无水硫酸镁干燥,过滤,在20℃以下减压浓缩得9.0g异腈化合物式Ⅲ,收率97.3%。Dissolve 10.2g of 2-(trifluoromethyl)phenylacetamide (0.05mol) in 100mL of dichloroethane, add 12.6g of triethylamine (0.125mol), lower the temperature of the reaction system to below -10°C, drop Add 0.05 mol of phosphorus oxychloride, and the dropwise addition is completed in about 20 minutes. Control the reaction temperature below 0°C and continue to stir for 1 hour, then raise the temperature to 25-30°C, and add 20% sodium carbonate solution dropwise to the reaction solution, and the dropwise addition is completed Then continue to stir for 5-10 minutes, let stand to separate layers, wash the organic phase twice with 5% sodium carbonate solution, dry with anhydrous magnesium sulfate, filter, and concentrate under reduced pressure below 20°C to obtain 9.0 g of isocyanide compound formula III, Yield 97.3%.

实施例3 4-甲基-5-[2-(三氟甲基)苯基]-1H-吡咯-3-羧酸乙酯的制备(埃沙西林酮中间体化合物Ⅳ)Example 3 Preparation of 4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid ethyl ester (Exacillinone intermediate compound IV)

Figure PCTCN2022080532-appb-000016
Figure PCTCN2022080532-appb-000016

在氩气氛围中,向500mL 1,4-二氧六环溶剂中加入氧化亚铜0.36g(2.5mmol,0.05eq)和DBU 7.65g(0.05mol,1eq),2-丁炔酸乙酯6.73g(0.06mol,1.2eq)和异腈化合物式Ⅲ9.25g(0.05mol,1eq),在100℃条件下搅拌2小时,检测反应完全,将反应液冷却至室温,过滤,向滤液中加入乙酸乙酯和饱和氯化钠水溶液,萃取,有机相用无水硫酸钠干燥,过滤,浓缩除去溶剂,纯化得到4-甲基-5-[2-(三氟甲基)苯基]-1H-吡咯-3-羧酸乙酯12.3g,收率83%。In an argon atmosphere, add cuprous oxide 0.36g (2.5mmol, 0.05eq) and DBU 7.65g (0.05mol, 1eq) to 500mL 1,4-dioxane solvent, ethyl 2-butynoate 6.73 g (0.06mol, 1.2eq) and 9.25g (0.05mol, 1eq) of the isonitrile compound formula III, stirred at 100°C for 2 hours, the reaction was detected to be complete, the reaction solution was cooled to room temperature, filtered, and acetic acid was added to the filtrate ethyl ester and saturated aqueous sodium chloride, extracted, the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated to remove the solvent, and purified to obtain 4-methyl-5-[2-(trifluoromethyl)phenyl]-1H- 12.3 g of ethyl pyrrole-3-carboxylate, yield 83%.

1H-NMR(400MHz,DMSO-d 6)δ8.43(s,1H),7.79(m,1H),7.63-7.39(m,4H),4.33-4.29(m,2H),2.19(s,3H),1.37-1.34(m,3H)。 1 H-NMR (400MHz, DMSO-d 6 )δ8.43(s,1H),7.79(m,1H),7.63-7.39(m,4H),4.33-4.29(m,2H),2.19(s, 3H), 1.37-1.34 (m, 3H).

实施例4 1-(2-羟基乙基)4-甲基-5-[2-(三氟甲基)苯基]-1H-吡咯-3-羧酸的制备Example 4 Preparation of 1-(2-hydroxyethyl) 4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid

Figure PCTCN2022080532-appb-000017
Figure PCTCN2022080532-appb-000017

在室温下将4-甲基-5-[2-(三氟甲基)苯基]-1H-吡咯-3-羧酸乙酯15g(0.05mol,1eq)溶解于300ml的二氯乙烷,加入四乙基溴化铵10.1g(0.05mol,1eq),在搅拌条件下向反应液中滴加20%的NaOH水溶液(100ml),约30min滴完,在室温下继续反应1h,然后将反应液加热到60℃反应2h,点板检测反应完全,将反应液冷却至室温,用2N的盐酸调节pH至5~6,静置分层,水相用二氯甲烷萃取2次,合并有机相,干燥浓缩,得到1-(2-羟基乙基)4-甲基-5-[2-(三氟甲基)苯基]-1H-吡咯-3-羧酸14.7g,收率94%。4-Methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid ethyl ester 15g (0.05mol, 1eq) was dissolved in 300ml of dichloroethane at room temperature, Add 10.1 g (0.05 mol, 1 eq) of tetraethylammonium bromide, add 20% NaOH aqueous solution (100 ml) dropwise to the reaction solution under stirring conditions, drop it for about 30 min, continue to react at room temperature for 1 h, and then react The solution was heated to 60°C and reacted for 2 hours, and the reaction was detected by spotting the plate. The reaction solution was cooled to room temperature, and the pH was adjusted to 5-6 with 2N hydrochloric acid, and the layers were allowed to stand. The aqueous phase was extracted twice with dichloromethane, and the organic phases were combined. , dried and concentrated to obtain 14.7 g of 1-(2-hydroxyethyl)4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid with a yield of 94%.

实施例6 1-(2-羟乙基)-N-[4-(甲磺酰基)苯基]-4-甲基-5-[2-(三氟甲基)苯基]-1H-吡咯-3-羧酰胺的制备Example 6 1-(2-hydroxyethyl)-N-[4-(methylsulfonyl)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole - Preparation of 3-carboxamide

Figure PCTCN2022080532-appb-000018
Figure PCTCN2022080532-appb-000018

将4-甲磺酰基苯胺3.77g(0.022mol,1.1eq),埃沙西林酮中间体化合物式Ⅴ6.26g(0.02mol,1.0eq),HOBT 4.05g(0.03mol,1.5eq),EDCI 5.75g(0.03mol,1.5eq),DIPEA 5.16g(0.04mol,2.0eq)加入到反应瓶中,加入300mL DCM,室温条件下搅拌反应,TLC跟踪反应,待反应完全后,加入饱和氯化钠水溶液100ml萃取,有机相用饱和氯化钠水溶液洗涤3次,有机相经无水硫酸钠干燥,过滤,蒸去溶剂,用乙酸乙酯:石油醚体积比为1:1的混合溶剂纯化得8.4g,收率90%。3.77g (0.022mol, 1.1eq) of 4-methylsulfonylaniline, 6.26g (0.02mol, 1.0eq), 4.05g (0.03mol, 1.5eq), EDCI 5.75g (0.03mol, 1.5eq), DIPEA 5.16g (0.04mol, 2.0eq) was added to the reaction flask, 300mL DCM was added, the reaction was stirred at room temperature, and the reaction was tracked by TLC. After the reaction was complete, 100ml of saturated aqueous sodium chloride solution was added Extraction, the organic phase was washed 3 times with saturated aqueous sodium chloride solution, the organic phase was dried over anhydrous sodium sulfate, filtered, the solvent was evaporated, and purified with a mixed solvent of ethyl acetate:petroleum ether volume ratio of 1:1 to obtain 8.4g, Yield 90%.

1H-NMR(400MHz,DMSO-d 6)δ:7.94-7.90(m,2H),7.86-7.78(m,3H),7.69-7.65(m,2H),7.64-7.62(m,1H),7.36-7.33(m,1H),7.29(s,1H)4.39-4.35(m,2H),3.29-3.10(m,5H),2.18(s,3H)。 1 H-NMR (400MHz, DMSO-d 6 ) δ: 7.94-7.90(m,2H), 7.86-7.78(m,3H), 7.69-7.65(m,2H), 7.64-7.62(m,1H), 7.36-7.33 (m, 1H), 7.29 (s, 1H), 4.39-4.35 (m, 2H), 3.29-3.10 (m, 5H), 2.18 (s, 3H).

比较例1Comparative example 1

参考现有文献CN101006052A中实施例16的制备方法,将原料氰基乙酸甲酯更换为氰基乙酸乙酯,制备4-甲基-5-[2-(三氟甲基)苯基]-1H-吡咯-3-羧酸乙酯,收率为21.5%。With reference to the preparation method of Example 16 in the existing document CN101006052A, the raw material methyl cyanoacetate is replaced with ethyl cyanoacetate to prepare 4-methyl-5-[2-(trifluoromethyl)phenyl]-1H - Ethyl pyrrole-3-carboxylate, yield 21.5%.

比较例2Comparative example 2

参考现有文献WO2010098286A1中参考例3的制备方法,制得1-(2-羟乙基)-N-[4-(甲磺酰基)苯基]-4-甲基-5-[2-(三氟甲基)苯基]-1H-吡咯-3-羧酰胺,总收率为7.6%。Referring to the preparation method of Reference Example 3 in the existing document WO2010098286A1, 1-(2-hydroxyethyl)-N-[4-(methylsulfonyl)phenyl]-4-methyl-5-[2-( Trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide, the total yield was 7.6%.

以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and changes. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included within the protection scope of the present invention.

Claims (10)

一种新的埃沙西林酮中间体化合物式Ⅳ的合成方法,该合成方法包括下列步骤:A kind of synthetic method of new ethacillinone intermediate compound formula IV, this synthetic method comprises the following steps: (1)将原料2-(三氟甲基)苯乙酸在惰性溶剂中,碱存在条件下,与氯甲酸乙酯或氯甲酸异丁酯反应生成混合酸酐,而后再与氨反应得到相应的酰胺化合物式Ⅱ;(1) The raw material 2-(trifluoromethyl)phenylacetic acid is reacted with ethyl chloroformate or isobutyl chloroformate in an inert solvent in the presence of a base to form a mixed anhydride, and then reacted with ammonia to obtain the corresponding amide Compound formula II; (2)步骤(1)得到的酰胺化合物式Ⅱ在脱水剂和缚酸剂存在条件下经脱水反应制备得到异腈化合物式Ⅲ;(2) The amide compound formula II obtained in step (1) is prepared through a dehydration reaction in the presence of a dehydrating agent and an acid-binding agent to obtain an isonitrile compound formula III; (3)步骤(2)得到的异腈化合物式Ⅲ与2-丁炔酸乙酯在碱和金属催化剂存在条件下环化形成吡咯环化合物式Ⅳ;(3) The isonitrile compound formula III obtained in step (2) is cyclized with ethyl 2-butynoate to form the pyrrole ring compound formula IV in the presence of a base and a metal catalyst; 工艺路线如下所示:The process route is as follows:
Figure PCTCN2022080532-appb-100001
Figure PCTCN2022080532-appb-100001
根据权利要求1所述的合成方法,其特征在于,步骤(1)中所述的惰性溶剂包括但不限于卤代烃、苯、甲苯、乙醚、二甲苯、硝基苯、乙腈组成的组中的一种或多种;所述的碱为咪唑、吡啶、四丁基氟化铵、2,6-二甲基吡啶、碳酸钾、N,N-二异丙基乙胺、碳酸钠、三乙胺中的一种或多种;2-(三氟甲基)苯乙酸与碱的摩尔比为1:0.5~1;2-(三氟甲基)苯乙酸与氯甲酸乙酯或氯甲酸异丁酯的摩尔比为1:1~1.5;反应温度为0℃~室温;反应时间为12小时~36小时。The synthetic method according to claim 1, wherein the inert solvent described in step (1) includes but is not limited to the group consisting of halogenated hydrocarbons, benzene, toluene, ether, xylene, nitrobenzene, and acetonitrile one or more; the base is imidazole, pyridine, tetrabutylammonium fluoride, 2,6-lutidine, potassium carbonate, N,N-diisopropylethylamine, sodium carbonate, three One or more of ethylamines; the molar ratio of 2-(trifluoromethyl)phenylacetic acid to base is 1:0.5~1; 2-(trifluoromethyl)phenylacetic acid and ethyl chloroformate or chloroformic acid The molar ratio of isobutyl ester is 1:1~1.5; the reaction temperature is 0°C~room temperature; the reaction time is 12 hours~36 hours. 根据权利要求1所述的合成方法,其特征在于,优选地,步骤(2)中所述的脱水剂为P 2O 5,PCl 3,SOCl 2,COCl 2,ArSO 2Cl,POCl 3中的一种或多种;所述缚酸剂为有机碱或无机碱,所述无机碱为碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾、叔丁醇钾等;所述有机碱为三乙胺,二异丙胺;所述溶剂选用卤代烷烃,二氯甲烷,二氯乙烷。 The synthesis method according to claim 1, characterized in that, preferably, the dehydrating agent described in step (2) is P 2 O 5 , PCl 3 , SOCl 2 , COCl 2 , ArSO 2 Cl, POCl 3 One or more; the acid-binding agent is an organic base or an inorganic base, and the inorganic base is sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium tert-butoxide, etc.; the organic base is triethyl Amine, diisopropylamine; Described solvent selects haloalkane, methylene dichloride, ethylene dichloride for use. 根据权利要求1所述的合成方法,其特征在于,步骤(3)中所述的碱为Pr 3N,吡啶pyridine,DBU,TEEDA;所述的金属催化剂为Cu 2O,CuCl,CuI,CuBr,Cu(OMe) 2,铜粉。 The synthetic method according to claim 1, wherein the alkali described in step (3) is Pr 3 N, pyridine pyridine, DBU, TEEDA; the metal catalyst is Cu 2 O, CuCl, CuI, CuBr , Cu(OMe) 2 , copper powder. 一种新的埃沙西林酮中间体化合物式Ⅴ的合成方法,其合成方法包括下列步骤:由权利要求1~4所述的合成方法得到的吡咯环化合物式Ⅳ在溶剂中,碱存在条件下,与
Figure PCTCN2022080532-appb-100002
反应制备得到化合物式Ⅴ;中间体化合物式Ⅴ的结构式如下所示:
A kind of synthetic method of new eschacillinone intermediate compound formula V, its synthetic method comprises the following steps: the pyrrole ring compound formula IV obtained by the synthetic method described in claims 1 to 4 is in a solvent, under the condition of alkali presence ,and
Figure PCTCN2022080532-appb-100002
Reaction preparation obtains compound formula V; The structural formula of intermediate compound formula V is as follows:
Figure PCTCN2022080532-appb-100003
Figure PCTCN2022080532-appb-100003
所述X为卤素,所述A为羟基或卤素。The X is halogen, and the A is hydroxyl or halogen.
根据权利要求5所述的合成方法,其特征在于,所述溶剂为醇溶剂,卤代烃溶剂,芳族烃类溶剂,醚类溶剂或酰胺类溶剂;所述的醇溶剂包括但不限于乙醇;所述的卤代烃溶剂包括但不限于二氯甲烷或氯仿;所述的芳族烃类溶剂包括但不限于甲苯、苯、二甲苯或硝基苯;所述的醚类溶剂包括但不限于四氢呋喃、1,4-二氧六环或所述的酰胺类溶剂包括但不限于N,N-二甲基乙酰胺、N,N-二甲基甲酰胺;所述碱为氢氧化钠、氢氧化钾、氢氧化锂、叔丁醇钠、叔丁醇钾、碳酸铯、氢化钠、碳酸钾、碳酸钠、4-二甲基氨基吡啶、N,N-二异丙基乙胺、三乙胺或吡啶;优选氢氧化钠、氢氧化锂;该步骤反应温度为室温~80℃,优选为室温~60℃,反应时间为1~20小时,优选为2~3小时。The synthesis method according to claim 5, wherein the solvent is an alcohol solvent, a halogenated hydrocarbon solvent, an aromatic hydrocarbon solvent, an ether solvent or an amide solvent; the alcohol solvent includes but is not limited to ethanol The halogenated hydrocarbon solvent includes but not limited to methylene chloride or chloroform; the aromatic hydrocarbon solvent includes but not limited to toluene, benzene, xylene or nitrobenzene; the ether solvent includes but not limited to Limited to tetrahydrofuran, 1,4-dioxane or the amide solvents include but not limited to N,N-dimethylacetamide, N,N-dimethylformamide; the base is sodium hydroxide, Potassium hydroxide, lithium hydroxide, sodium tert-butoxide, potassium tert-butoxide, cesium carbonate, sodium hydride, potassium carbonate, sodium carbonate, 4-dimethylaminopyridine, N,N-diisopropylethylamine, tri Ethylamine or pyridine; preferably sodium hydroxide or lithium hydroxide; the reaction temperature in this step is room temperature to 80°C, preferably room temperature to 60°C, and the reaction time is 1 to 20 hours, preferably 2 to 3 hours. 一种新的埃沙西林酮的合成方法,其特征在于,由权利要求5~6所述的合成方法得到的埃沙西林酮中间体化合物式Ⅴ与4-甲磺酰基苯胺在缩合剂作用下经缩合反应得到化合物式Ⅵ,其中化合物式Ⅵ的结构式如下所示:A kind of synthetic method of new ethacillinone, it is characterized in that, the ethacillinone intermediate compound formula V obtained by the synthetic method described in claim 5~6 and 4-methanesulfonyl aniline are under the action of condensing agent Compound formula VI is obtained through condensation reaction, wherein the structural formula of compound formula VI is as follows:
Figure PCTCN2022080532-appb-100004
Figure PCTCN2022080532-appb-100004
根据权利要求7所述的合成方法,其特征在于,所述的缩合剂为1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐(EDCI)和1-羟基苯并三氮唑(HOBT),溶剂为干燥的N,N-二甲基甲酰胺(DMF),此外还要加入一定量的碱,常用的碱为N,N-二异丙基乙胺(DIPEA)、三乙胺、吡啶、六氟磷酸苯并三唑-1-基-氧基三吡咯烷基(PyBop),优选N,N-二异丙基乙胺(DIPEA)。The synthetic method according to claim 7, wherein the condensing agent is 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) and 1-hydroxybenzene And triazole (HOBT), the solvent is dry N,N-dimethylformamide (DMF), in addition to adding a certain amount of alkali, the commonly used alkali is N,N-diisopropylethylamine (DIPEA ), triethylamine, pyridine, benzotriazol-1-yl-oxytripyrrolidinyl hexafluorophosphate (PyBop), preferably N,N-diisopropylethylamine (DIPEA). 一种新的埃沙西林酮的制备方法,其特征在于,由权利要求5~6所述的合成方法得到的埃沙西林酮中间体化合物式Ⅴ与合适的酰化试剂反应得到酰氯化合物Ⅶ,酰氯化合物式Ⅶ再 与4-甲磺酰基苯胺发生酰基化反应得到化合物Ⅵ,其中酰氯化合物式Ⅶ的结结构式如下所示:A kind of preparation method of new oxacillinone, it is characterized in that, the oxacillinone intermediate compound formula V obtained by the synthesis method described in claims 5 to 6 reacts with a suitable acylating reagent to obtain acid chloride compound VII, The acid chloride compound formula VII is acylated with 4-methanesulfonylanilide to obtain compound VI, wherein the structural formula of the acid chloride compound formula VII is as follows:
Figure PCTCN2022080532-appb-100005
Figure PCTCN2022080532-appb-100005
根据权利要求9所述的合成方法,其特征在于,所述的酰化试剂为草酰氯,所述的酰基化反应优选在碱和溶剂存在的条件下进行,所述的碱为有机碱或无机碱,包括但不限于三乙胺、N,N-二异丙基乙胺;所述的溶剂为卤代烃溶剂,芳族烃类溶剂,醚类溶剂或酰胺类溶剂;所述的卤代烃溶剂包括但不限于二氯甲烷或氯仿;所述的芳族烃类溶剂包括但不限于甲苯、苯、二甲苯或硝基苯;所述的醚类溶剂包括但不限于四氢呋喃、1,4-二氧六环或所述的酰胺类溶剂包括但不限于N,N-二甲基乙酰胺、N,N-二甲基甲酰胺。The synthetic method according to claim 9, wherein the acylating agent is oxalyl chloride, and the acylating reaction is preferably carried out in the presence of a base and a solvent, and the base is an organic base or an inorganic base. Alkalis, including but not limited to triethylamine, N,N-diisopropylethylamine; the solvent is a halogenated hydrocarbon solvent, aromatic hydrocarbon solvent, ether solvent or amide solvent; the halogenated Hydrocarbon solvents include but not limited to dichloromethane or chloroform; described aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene; described ether solvents include but not limited to tetrahydrofuran, 1,4 - dioxane or the amide solvents include but not limited to N,N-dimethylacetamide, N,N-dimethylformamide.
PCT/CN2022/080532 2021-09-10 2022-03-13 Synthesis method for esaxerenone and intermediate thereof Ceased WO2023035571A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111063792.3 2021-09-10
CN202111063792.3A CN115784961A (en) 2021-09-10 2021-09-10 Synthesis method of oxacillin and intermediate thereof

Publications (1)

Publication Number Publication Date
WO2023035571A1 true WO2023035571A1 (en) 2023-03-16

Family

ID=85473617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/080532 Ceased WO2023035571A1 (en) 2021-09-10 2022-03-13 Synthesis method for esaxerenone and intermediate thereof

Country Status (2)

Country Link
CN (1) CN115784961A (en)
WO (1) WO2023035571A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117510400A (en) * 2023-11-29 2024-02-06 山西永津集团有限公司 Preparation method of 6-bromo-2-chloro-3-nitropyridine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119306645A (en) * 2023-07-12 2025-01-14 广东东阳光药业股份有限公司 Method for preparing pyrrolamide compound and intermediate thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1844020A1 (en) * 2005-01-10 2007-10-17 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
CN101679243A (en) * 2007-04-09 2010-03-24 第一三共株式会社 atropisomer of pyrrole derivative
WO2010098286A1 (en) * 2009-02-25 2010-09-02 第一三共株式会社 Pharmaceutical preparation containing mineralcorticoid receptor antagonist
CN102186817A (en) * 2008-10-08 2011-09-14 埃克塞利希斯股份有限公司 Atropisomers of (hydroxyalkyl) pyrrole derivatives
CN105164105A (en) * 2013-04-10 2015-12-16 第一三共株式会社 Crystallization of pyrrole derivatives and its preparation method
CN105473552A (en) * 2013-08-27 2016-04-06 第一三共株式会社 Method for producing pyrrole derivative, and intermediate thereof
CN112707854A (en) * 2019-10-25 2021-04-27 广东东阳光药业有限公司 Pyrrole amide compound and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102078528B1 (en) * 2018-04-18 2020-02-19 성균관대학교산학협력단 Pharmaceutical Composition for preventing or treating dementia or cognitive disorder using novel HDAC6 inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1844020A1 (en) * 2005-01-10 2007-10-17 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
CN101679243A (en) * 2007-04-09 2010-03-24 第一三共株式会社 atropisomer of pyrrole derivative
CN102186817A (en) * 2008-10-08 2011-09-14 埃克塞利希斯股份有限公司 Atropisomers of (hydroxyalkyl) pyrrole derivatives
WO2010098286A1 (en) * 2009-02-25 2010-09-02 第一三共株式会社 Pharmaceutical preparation containing mineralcorticoid receptor antagonist
CN105164105A (en) * 2013-04-10 2015-12-16 第一三共株式会社 Crystallization of pyrrole derivatives and its preparation method
CN105473552A (en) * 2013-08-27 2016-04-06 第一三共株式会社 Method for producing pyrrole derivative, and intermediate thereof
CN112707854A (en) * 2019-10-25 2021-04-27 广东东阳光药业有限公司 Pyrrole amide compound and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU YUXI, DAI HONGXING, DU YUCHENG, DENG JIGUANG, ZHANG LEI, ZHAO ZHENXUAN, AU CHAK TONG: "Controlled preparation and high catalytic performance of three-dimensionally ordered macroporous LaMnO3 with nanovoid skeletons for the combustion of toluene", JOURNAL OF CATALYSIS, ACADEMIC PRESS, DULUTH, MN., US, vol. 287, 1 March 2012 (2012-03-01), US , pages 149 - 160, XP093045756, ISSN: 0021-9517, DOI: 10.1016/j.jcat.2011.12.015 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117510400A (en) * 2023-11-29 2024-02-06 山西永津集团有限公司 Preparation method of 6-bromo-2-chloro-3-nitropyridine

Also Published As

Publication number Publication date
CN115784961A (en) 2023-03-14

Similar Documents

Publication Publication Date Title
EP3189053B1 (en) An improved process for the preparation of apixaban and intermediates thereof
CN102812020B (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
KR101472686B1 (en) Method for preparation of benzimidazole derivatives
US10927095B2 (en) Processes for the preparation of Niraparib and intermediates thereof
CN112592344B (en) Indolo [2,3-b ] indole derivative and synthetic method thereof
WO2023035571A1 (en) Synthesis method for esaxerenone and intermediate thereof
CN109988077A (en) A kind of synthetic method and intermediate of A Palu amine
CN114805308A (en) Method for synthesizing aminopyrimidine FAK inhibitor compound
WO2018153380A1 (en) Preparation of velpatasvir and derivative thereof
CN106699595A (en) A kind of preparation method of lacosamide
WO2014067237A1 (en) Telmisartan preparation method and intermediate thereof
CN112047879A (en) A kind of method of copper-catalyzed selective synthesis of halogenated aromatic amines
CN115557823B (en) A method for synthesizing amide compounds
CN112028827A (en) Preparation method of neratedlol key intermediate
CN112574087B (en) Synthetic method of 3-aminopyrrolidine hydrochloride
JP2018516949A (en) A novel method for preparing enzalutamide
CN113336703B (en) Synthesis of 1,3,4, 5-tetrasubstituted 1H-pyrazole derivatives
CN113968815B (en) A method for synthesizing a thiazaspirocarboxylic acid compound, its intermediate, and the method for synthesizing it.
CN104230885A (en) A preparing method of imatinib
JP2008531642A (en) Method for obtaining pharmaceutically active compound irbesartan and synthetic intermediates thereof
CN109879805B (en) Preparation method of apatinib
CN114920655A (en) A kind of preparation method of 2-fluoro-3-trifluoromethylaniline
CN106588765A (en) Method for hydroxylation of nitrogen oxide C2-position
CN113999175B (en) Synthesis method of visible light catalytic sulfonyl substituted isoquinoline-1, 3 (2H, 4H) -dione
CN104262338A (en) Synthetic method of apixaban and intermediate thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22866049

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22866049

Country of ref document: EP

Kind code of ref document: A1